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Colorectal cancer (CRC) metastasizes mainly to the liver, which accounts for
the majority of CRC-related deaths. Here it is shown that metastatic cells
undergo specific chromatin remodeling in the liver. Hepatic growth factor
(HGF) induces phosphorylation of PU.1, a pioneer factor, which in turn binds
and opens chromatin regions of downstream effector genes. PU.1 increases
histone acetylation at the DPP4 locus. Precise epigenetic silencing by
CRISPR/dCas9KRAB or CRISPR/dCas9HDAC revealed that individual
PU.1-remodeled regulatory elements collectively modulate DPP4 expression
and liver metastasis growth. Genetic silencing or pharmacological inhibition
of each factor along this chromatin remodeling axis strongly suppressed liver
metastasis. Therefore, microenvironment-induced epimutation is an
important mechanism for metastatic tumor cells to grow in their new niche.
This study presents a potential strategy to target chromatin remodeling in
metastatic cancer and the promise of repurposing drugs to treat metastasis.
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1. Introduction
Metastasis of cancer cells from primary
sites to distant organs accounts for the ma-
jority of cancer-related deaths. Colorectal
cancer (CRC) is a leading cause of cancer
mortality in the United States, and its 5-
year survival rate drops significantly once
patients develop distant metastases,[1] in
which liver is the most common site for
CRC metastases.[2,3]
CRC metastases have not been consis-
tently associated with specific oncodriver
mutations.[4–7] Therefore, current CRC
chemotherapy does not distinguish be-
tween different metastatic loci. Neverthe-
less, metastatic cells have to adapt to their
new niche as suggested by the “seed and
soil” theory,[8] in which microenvironment
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factors including the extracellular matrix (ECM), vasculature, se-
creted factors, and myeloid cells can elicit changes in metastatic
tumor cells.[9,10] Mixed response to chemotherapy between pri-
mary CRC tumors and metastases occurs in a significant fraction
of patients,[11] supporting the existence of important biological
differences between the two.
The liver environment is different from that of the colon
in terms of cellular composition and metabolism. Metabolic
reprogramming has been shown to promote CRC liver
metastasis.[12–15] In this study, we applied epigenetic and
transcriptomic profiling techniques, including transposase-
accessible chromatin and sequencing (ATAC-seq), multiplexed
indexed T7 chromatin immunoprecipitation (Mint-ChIP), and
RNA-seq, on synchronous primary CRC tumors and liver metas-
tases from an in vivo CRC orthotopic-metastasis model, which
revealed systematic chromatin alterations between liver metas-
tases and primary tumors. Cross-validation with clinical datasets
identified a major chromatin remodeling axis whereby hepatic
growth factor (HGF) induces phosphorylation of PU.1, a pioneer
transcription factor that opens up closed chromatin and recruits
additional epigenetic modifiers.[16–19] PU.1 binding was enriched
in chromatin regions that became accessible in liver metastases.
In particular, it activated dipeptidylpeptidase 4 (DPP4) through
its three enhancers and promoter, each of which was shown
to modulate liver metastasis in vivo by CRISPR/dCas9KRAB.
Pharmacological inhibition or genetic silencing of HGF, PU.1,
or DPP4 suppressed liver metastases.
2. Results
2.1. Chromatin Remodeling Occurs in CRC Liver Metastases
We used an in vivo orthotopic CRC metastatic model obtained
by injecting mCherry- and luciferase-labeled human CRC cells
into the cecal wall of immunocompromised NOD.Cg-Prkdcscid
Il2rgtm1wjl/SzJ (NSG) mice as previously described.[12,20] We per-
formed cecum injection with cells from a common CRC line,
HT29, and three liver metastases patient-derived xenografts
(PDX) – CRC57, CRC12x, and CRC247 (Table S1, Supporting In-
formation). The injected CRC cells first formed cecal tumors then
metastasized to the liver.
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To investigate changes in the open chromatin state in primary
CRC and liver metastases, we performed ATAC-seq on the pri-
mary CRC and liver metastatic CRC tumors collected from the
in vivo model five weeks after injection (Figure S1A, Supporting
Information).[21] To avoid contamination from stromal cells, har-
vested CRC tumors from ceca and livers of tumor-bearing mice
were dissociated into single cells and subjected to fluorescence-
activated cell sorting (FACS) based on mCherry fluorescence lev-
els (Figure S1B, Supporting Information).
We obtained high-quality ATAC-seq libraries from both pri-
mary and metastatic tumors with consistency across biological
replicates (N = 4 mice), as reflected by plots of irreproducible dis-
covery rate (IDR) and representative fragment distribution (Fig-
ure S1C,D, Supporting Information). Across the four CRC mod-
els, the global chromatin accessibility between liver metastases
and primary CRC was largely similar, as shown by Circos plots
(Figure 1A and Figure S1E, Supporting Information), as was the
overall chromatin accessibility around a gene body (Figure 1B
and Figure S1F, Supporting Information). These results suggest
that metastatic cells mostly retain their CRC identity. Neverthe-
less, a fraction of the chromatin accessibility peaks was signifi-
cantly different between primary and metastatic tumor cells ac-
cording to DiffBind,[22] as shown by hierarchical heatmaps of
the 1000 open chromatin regions with the highest variance (Fig-
ure 1C and Figure S1G, Table S5, Supporting Information). Most
of the altered regions were in intronic or intergenic regions where
cis-regulatory elements or enhancers locate (Figure 1D and Fig-
ure S1H, Supporting Information). We further associated the
altered chromatin regions with putative genes under their con-
trol by annotating to the nearest transcription start sites (TSS)
(Figure 1E and Figure S1I, Supporting Information). Gene On-
tology analyses demonstrated the upregulation of transcription
regulation and DNA binding pathways in the liver metastases
compared to the primary CRC (Figure 1F and Figure S1J, Sup-
porting Information).[23] Collectively, the ATAC-seq analyses sug-
gest that although metastatic cells largely resemble primary CRC
cells, they undergo distinct chromatin remodeling.
2.2. DPP4 is Upregulated in CRC Liver Metastases
We performed RNA-seq to compare the transcriptomic states be-
tween primary CRC and liver metastases collected from the in
vivo model. Consistent with the ATAC-seq results, a fraction of
genes was differentially expressed (DE) although most remained
unchanged (Figure 2A, Table S6, Supporting Information). In-
tegrated analysis of the ATAC-seq and RNA-seq profiling identi-
fied eight genes that are enriched in liver metastases (Figure 2B).
We cross-validated the upregulated genes with an RNA microar-
ray dataset that contains 39 primary CRC and 74 liver metastases
from stage IV CRC patients (GEO:GSE41568).[24] DPP4 and MAF
were the most upregulated in the liver metastases in all three
datasets (Figure 2B,C, and Figure S2A, Supporting Information).
We further validated the expression of DPP4 and MAF in an-
other clinical dataset containing RNA-seq results from paired pa-
tient primary CRC and liver metastases (SRR2089755), and both
of the genes were significantly upregulated in liver metastases
(Figure 2D and Figure S2B, Supporting Information). In liver
metastatic CRC cells, DPP4 had enriched open chromatin in its
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promoter and three enhancer regions (Figure 2E), but MAF only
had open chromatin changes around its promoter (Figure S2C,
Supporting Information).
We supplemented the ATAC-seq open chromatin maps with
high-resolution annotation of the H3K27ac histone activation
marker using Mint-ChIP, a technique that requires far fewer cells
than conventional ChIP-seq and is hence more compatible with
the in vivo metastasis model.[25] Consistent with chromatin ac-
cessibility results, Mint-ChIP showed that the DPP4 promoter
and three enhancers harbored more H3K27ac histone activation
markers in CRC liver metastases than in primary CRC tumors
(Figure 2F and Figure S2D, Supporting Information).
To further confirm the upregulation of DPP4 in clinical CRC
liver metastases, we acquired tissues from ten paired primary
CRC and liver metastases (Table S2, Supporting Information).
RT-qPCR showed that DPP4 was upregulated in liver metastases
(Figure 2G). The four sample pairs with enough remaining tissue
mass for Western blot analysis had higher DPP4 protein levels in
liver metastases versus primary CRC (Figure 2H). IHC staining
of a tissue array containing paired primary CRC tumors and liver
metastases from 16 patients also showed higher DPP4 staining
levels in liver metastases (Figure 2I and Table S3, Supporting
Information). We then cultured organoids derived from freshly
collected specimens of synchronous primary CRC and liver
metastases from two patients (Figure S3A and Table S4, Sup-
porting Information). Consistent with our in vivo results, DPP4
protein levels were higher in liver metastases-derived organoids
(Figure 2J).
Liver metastases had significantly higher levels of DPP4 than
the primary CRC tumors in HT29 and CRC57 from the in
vivo orthotopic-metastasis model (Figure 2K). Consistent with
RNA-seq and ATAC-seq profiling results, ChIP-qPCR confirmed
that histone activation markers H3K27ac, H3K4me1, H3K4me3,
and H3K9ac in the DPP4 promoter were significantly elevated in
CRC liver metastases compared to primary CRC (Figure 2L,M).
In the two pairs of matched patient-derived organoids, H3K27ac
and H3K4me3 levels in the DPP4 promoter region were con-
sistently higher in liver metastases-derived organoids than
in matched primary CRC-derived organoids (Figure S3B,C,
Supporting Information).
To investigate whether DPP4 expression is correlated with clin-
ical outcomes, we analyzed DPP4 expression and CRC progres-
sion based on the data from 98 CRC patients at Catalan Insti-
tute of Oncology.[26] The patients were divided into two cohorts,
DPP4high and DPP4low. 40% of DPP4high patients developed liver
metastasis, while only 14.8% DPP4low patients developed liver
metastasis (Figure 2N). In addition, DPP4high patients had signifi-
cantly higher rates of relapse and metastasis than the DPP4low pa-
tients (Figure 2O). Together, these data suggested that chromatin
remodeling upregulates DPP4 in CRC liver metastases, which is
associated with poor prognosis.
2.3. Silencing of DPP4 Suppresses CRC Liver Metastases
To investigate how DPP4 regulates tumor development, we used
CRISPR/Cas9 with two independent guide RNAs (gRNAs) to
knock out DPP4 in HT29 and two of the PDX cell lines, CRC57
and CRC247. DPP4 knockout efficiency was validated by Western
blot (Figure S4A,B,C, Supporting Information). Orthotopic injec-
tion mouse model showed that DPP4 knockout suppressed liver
metastases and prolonged survival (Figure 3A–C, Figure S4D,E,
Supporting Information). We further knocked out DPP4 using
CRISPR/Cas9 in patient-derived CRC organoids (Figure S4F,
Supporting Information) and intrahepatically injected them into
mice. Silencing of DPP4 significantly suppressed tumor growth
in the liver compared to the control (Figure S4G, Supporting
Information). We then knocked down Dpp4 in mouse CRC CT26
cells and injected them into the ceca of syngeneic immuno-
competent BALB/c mice (Figure S4H, Supporting Information).
shRNA, rather than CRISPR/Cas9, was used to silence Dpp4
to avoid potential complications by the host immune response
to CRISPR/Cas9 constructs.[27,28] Dpp4 knockdown suppressed
CT26 liver metastases in the immunocompetent mice and
prolonged their survival (Figure S4I,J, Supporting Information).
2.4. Epigenetic Silencing of DPP4 Regulatory Elements
Suppresses CRC Liver Metastases
To unravel which DPP4 regulatory elements contribute to liver
metastasis, we used CRISPR/dCas9KRAB system to precisely si-
lence each of the three enhancers and promoter.[29,30] We de-
signed 15, 18, 16, and 29 gRNAs spanning the entire regions of
the three enhancers and promoter, respectively (Figure S5A, Sup-
porting Information), and screened for DPP4 downregulation by
RT-qPCR (Figure S5B, Supporting Information). The gRNAs tar-
geting each regulatory element with the highest downregulation
efficiency on DPP4 were selected and validated by Western blot
(Figure S5C, Supporting Information). We then injected HT29
cells carrying CRISPR/dCas9KRAB and the selected or scrambled
gRNA into the mouse ceca. Each selected gRNA reduced tumor
growth and prolonged survival compared to the scrambled con-
trol (Figure S5D,E, Supporting Information). Therefore, in addi-
tion to the promoter, each of the three DPP4 enhancers located
in the opened chromatin modulates CRC liver metastases.
We then used CRISPR/dCas9HDAC to manipulate histone
acetylation within the DPP4 promoter.[31] We screened six DPP4
Figure 1. Epigenetic profiling on CRC liver metastases and CRC primary tumor. A) Circos plot revealing global chromatin accessibility change across
different chromosomes in HT29 liver metastases versus primary CRC tumor. B) Heatmap for chromatin accessibility across gene body from TSS to
transcription end site (TES) with 3 kb flanking regions in HT29 liver metastases versus primary CRC tumor. C) Hierarchical heatmap of 1000 chromatin
accessible regions with the highest variance between liver metastases and primary CRC tumor in HT29 and CRC57 across four biological replicates.
D) Distribution of enriched chromatin accessible regions across the genome in HT29 liver metastases versus primary CRC tumor. E) MA-plot showing
the differentially enriched (DE) accessible chromatin regions in HT29 liver metastases versus primary CRC tumor. F) Gene Ontology (GO) analysis on
molecular functions for DE accessible chromatin regions in HT29 liver metastases versus primary CRC tumor. LM, liver metastases. CP, CRC primary
tumor.
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gRNAs targeting the opened chromatin regions in the DPP4 pro-
moter (Figure S5F, Supporting Information) and the two selected
(g5 and g18) significantly suppressed H3K27ac, H3K9ac and
H3K4me3 levels (Figure 3D,E). We then orthotopically injected
the CRC cells carrying the scrambled or selected gRNAs into the
mouse ceca. The selected gRNAs suppressed tumor growth and
metastases and prolonged overall survival (Figure 3F,G).
2.5. A Pharmacological DPP4 Inhibitor Suppresses CRC Liver
Growth
Sitagliptin is a DPP4 inhibitor that has been approved for clin-
ical treatment of type II diabetes.[32] We investigated whether
Sitagliptin could prolong survival of metastatic liver disease by
using a spleen-injection liver metastasis model, in which injected
CRC cells reach the liver to form metastases without first form-
ing primary tumors, so that liver metastases are the sole contrib-
utor to death.[33] Sitagliptin treatment, which started three days
after spleen injection, significantly suppressed CRC growth in
the liver (Figure 3H) and increased the survival of tumor-bearing
mice (Figure 3I).
2.6. DPP4 Suppresses Tumor-Killing Neutrophils
Notably, downregulation of DPP4 did not affect migration and
proliferation of CRC cells in vitro (Figure S6, Supporting In-
formation). DPP4 has been shown to truncate the neutrophil
chemoattractants CXCL6 and CXCL10.[34–37] NSG mice lack ma-
ture T cells, B cells, and NK cells and have defective dendritic
cells and macrophages, but their neutrophils are intact.[38] We
analyzed neutrophil accumulation in the primary CRC and liver
metastases in orthopotic injection mouse model, finding that
knocking out DPP4 in CRC cells significantly increased neu-
trophil accumulation in both primary CRC and liver metastases
(Figure S7A–C, Supporting Information). Consistently, the intra-
hepatipic injection model also showed that knocking out DPP4
increased neutrophil cell infiltration in the liver (Figure S7D,E,
Supporting Information). We further analyzed the correlation be-
tween DPP4 and Myeloperoxidase (neutrophil marker gene) ex-
pression in clinical CRC liver metastases by integrating multiple
GEO datasets (GSE40367, GSE41258, and GSE49355). The neu-
trophil content is inversely correlated with DPP4 expression in
clinical CRC liver metastases (Figure S7F, Supporting Informa-
tion). Independently, immunochemistry on a CRC tissue array
containing 16 paired primary CRC tumors and liver metastases
indicated that DPP4 expression is much higher in liver metas-
tases than that in primary tumors (Figure 2I). Conversely, neu-
trophil content is low in liver metastases and high in primary
tumors (Figure S7G, Supporting Information).
Tumor-associated neutrophils have been shown to kill tumor
cells by physical contact.[39] We isolated and co-cultured neu-
trophils and DPP4 knockout CRC cells from the same HT29
or CRC57 tumors. Time-lapse microscopy showed that DPP4
knockout CRC cells had enhanced neutrophil recruitment for
physical contact (Figure S7H and Movies S1,S2, Supporting In-
formation). We then performed a trans-well migration assay with
active CXCL6 or DPP4-truncated CXCL6 in the lower cham-
ber and neutrophils isolated from the tumor-bearing mouse
in the top chamber. Both human and mouse CXCL6 signifi-
cantly enhanced neutrophil migration compared to the truncated
CXCL6 (Figure S7I, Supporting Information). To further eval-
uate the cytotoxic effect of CRC-associated neutrophils, we iso-
lated neutrophils from tumor-bearing mice and co-cultured with
luciferase-labeled HT29 and CRC57 cells. DPP4 knockout en-
hanced killing of tumor cells by neutrophils compared to the
scrambled control (Figure S7J, Supporting Information).
2.7. Pioneer Factor PU.1 Regulates DPP4 via its Enhancers and
Promoter
We analyzed binding motifs of potential upstream transcription
factors using JASPAR.[40] Among the 249 predicted transcription
factors, 14 had enriched chromatin accessible regions in liver
metastases; upon RNA-seq analysis, PU.1, FLI1, and TCF4 were
ranked as the top three (Figure 4A). Among these, PU.1 had the
best scores in all categories (Figure 4B).
PU.1 is a pioneer factor that opens up closed chromatin
and recruits additional epigenetic modifiers to regulate
hematopoiesis and fibrosis.[18,19] Nucleosome occupancy analysis
by NucleoATAC[41] demonstrated that nucleosomes are depleted
around the putative PU.1 binding motifs in liver metastasis-
enriched open chromatin regions; conversely, there is little
nucleosome remodeling in the primary CRC cells or in regions
constitutively open in both primary CRC and liver metastases
(Figure 4C). ChIP-qPCR confirmed PU.1 binding to the DPP4
promoter and enhancer regions in HT29, CRC57, and CRC247
cells (Figure 4D). Moreover, PU.1 binding to the DPP4 promoter
and three enhancer regions was significantly enriched in CRC
Figure 2. DPP4 is upregulated in CRC liver metastases. A) RNA-seq volcano-plot showing DE genes detected in HT29 liver metastases versus primary
CRC tumor. B) Integrated analysis of ATAC-seq, RNA-seq, and GEO dataset (GSE41568) of upregulated genes in liver metastases. C) Analysis of dif-
ferential DPP4 expression in GEO dataset (GSE41568) between primary CRC and liver metastases. D) Analysis of differential DPP4 expression in the
clinical RNA-seq dataset SRR2089755 from five matched patient liver metastases versus primary CRC tumor. E) ATAC-seq signal track showing DPP4-
associated open chromatin in liver metastases versus primary CRC tumor. F) Mint-ChIP signal track showing H3K27ac histone activation markers in
the DPP4 promoter and three enhancers in liver metastases versus primary CRC. G) RT-qPCR showing DPP4 expression levels in patient liver metas-
tases versus primary CRC tumors. H) Western blots showing DPP4 expression levels in paired primary CRC and liver metastases collected from four
patients. I) Representative IHC staining and evaluation of DPP4 expression measured on a tissue microarray that contains 16 paired primary CRC and
liver metastases. (Scale bar, 50 um). J) Western blots showing DPP4 expression levels in two paired patient-derived liver metastases and primary CRC
organoids. K) Western blots showing DPP4 expression levels in primary CRC and liver metastases derived from cecum-injected-HT29 and -CRC57 cells.
L,M) ChIP-qPCR analysis showing changes in H3K27ac, H3K4me1, H3K4me3, and H3K9ac levels on DPP4 promoter in liver metastases versus primary
CRC tumor. N) Correlation of DPP4 expression and clinicopathological features of 98 CRC patients. O) Kapla–Meier analysis of relapses of CRC patients
with high (N = 30) and low (N = 68) DPP4 expression levels in the tumors. LM, liver metastases. CP, CRC primary tumor. E1, E2, and E3, enhancer 1,
enhancer 2, and enhancer 3. Data represent the mean ± s.e.m. in (C) and (D), and mean ± s.d. in (G), (L), and (M). p-values were calculated based on
Student’s t-test in (C), (D), (G), (L), (M), and (N), and log-rank test in (O). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Figure 3. Ablation of DPP4 suppresses CRC progression. A,B) Images and quantifications of bioluminescence of NSG mice injected with A) luciferase-
labeled HT29 and B) CRC57 cells carrying scrambled (control) or DPP4 knockout (DPP4 KO1 or KO2) gRNA constructs. C) Survival analysis of NSG mice
injected with luciferase-labeled HT29 and CRC57 cells carrying scrambled (control) or DPP4 knockout (DPP4 KO1 or KO2) gRNA constructs. D) Western
blots showing downregulation of DPP4 by selected and scrambled gRNA tested in the CRISPR/dCas9HDAC system. E) ChIP-qPCR showing the effect of
CRISPR/dCas9HDAC system on DPP4 promoter-associated histone modification. F,G) Images and quantifications of F) bioluminescence and G) survival
analysis of NSG mice carrying scrambled and selected gRNA in the CRISPR/dCas9HDAC system. H,I) Images and quantifications of H) bioluminescence
and I) survival analysis of NSG mice receiving spleen-injection of HT29 cells with or without Sitagliptin oral gavage. Data represent the mean ± s.d.
p-value was calculated based on student’s t-test in (H), ANOVA and Tukey’s HSD post doc test in (A), (B), (E), and (F), and log-rank test in (C), (G),
and (I). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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cells isolated from the liver metastases relative to cells isolated
from the primary CRC tumors (Figure 4E). ChIP-qPCR in the
aforementioned organoids derived from synchronous patient
primary CRC and liver metastatic tumors (Figure S3A, Table S4,
Supporting Information) further confirmed the enrichment
of PU.1 binding in liver metastases (Figure 4F). PU.1 knock-
down suppressed DPP4 expression (Figure 4G) and decreased
H3K27ac, H3K4me1, H3K4me3, and H3K9ac histone markers
in DPP4 promoter-associated chromatin regions (Figure 4H).
2.8. PU.1 Promotes CRC Liver Metastasis
Consistent with the results from RNA-seq profiling of the in vivo
model, GSE41568 and SRR2089755 analysis, and IHC staining
showed elevated PU.1 expression in clinical CRC liver metastases
compared to primary CRC (Figure 5A–C), which was further
validated by Western blot of aforementioned pairs of primary
CRC and liver metastases tissue samples and patient-derived
organoids (Table S2,S4, Supporting Information) (Figure 5D,E).
PU.1 knockdown reduces the sizes of liver metastases (Fig-
ure 5F,H) and prolonged survival (Figure 5G–J) of mice bearing
either HT29 or CRC57 tumors.
2.9. HGF Upregulates DPP4 through Activation of PU.1
PU.1 activation requires phosphorylation to enhance its DNA
binding and co-factor recruitment.[42] Pathway analysis based on
liver metastases-enriched open chromatin regions identified by
ATAC-seq showed that receptor tyrosine kinase (RTK) pathways
were consistently activated in liver metastases of mice injected
with each of the four tested CRC cell lines (Figure 6A and Fig-
ure S8, Supporting Information). HGF is highly expressed in
the liver microenvironment and can facilitate tumor growth.[43]
Moreover, the HGF/c-Met pathway is one of the most impor-
tant RTK pathways in both the liver and advanced hepatocellular
carcinoma.[44] Recombinant HGF did not affect PU.1 expression
(Figure 6B) but significantly enhanced PU.1 phosphorylation in
HT29 and CRC57 cells, which was abrogated by the c-Met in-
hibitor PHA665752 (Figure 6C).
Phosphorylated PU.1 has been reported to initiate chromatin
remodeling through complexing with C/EBP𝛼/𝛽 and SWI/SNF-
related matrix-associated actin-dependent regulator of chromatin
subfamily B member 1 (SMARCB1).[45] Immunoprecipitation
confirmed that PU.1 complexed with C/EBP𝛼/𝛽 and SMARCB1
in HT29 and CRC57 cells (Figure 6D,E). HGF treatment signifi-
cantly increased the levels of H3K27ac, H3K4me1, and H3K9ac
markers in the DPP4 promoter region (Figure 6F). Recombinant
HGF upregulated DPP4 expression and this was abrogated by
PU.1 knockdown, which suggests that HGF enhances DPP4 ex-
pression via PU.1 (Figure 6G).
We then evaluated the therapeutic potential of Norleual, an
HGF inhibitor, on prolonging survival of metastatic liver disease
using the spleen injection liver metastasis model. Intraperitoneal
(i.p.) injection of Norleual, which started three days after spleen
injection, reduced tumor sizes in the liver and prolonged survival
(Figure 6H,I).
3. Discussion
Although CRC liver metastases are not associated with any
unique oncodriver mutation, this study demonstrates that
metastatic cells growing in the liver have undergone chromatin
remodeling. We identified a chromatin remodeling axis whereby
HGF in the liver environment induces phosphorylation of the pi-
oneer factor PU.1 in metastatic cells. Phosphorylated PU.1 mod-
ulates downstream regulatory elements to activate effector genes
such as DPP4, which promotes tumor growth. Targeting the
factors or regulatory elements along the axis resulted in strong
anti-tumor effects, which suggests that targeting this axis may
be a viable strategy against liver metastasis. For instance, DPP4
expression has been associated with poor CRC prognosis,[46] and
a recent epidemiology study revealed that diabetic patients with
CRC who were treated with DPP4 inhibitors had a statistically
significant survival advantage.[47] The HGF/PU.1/DPP4 axis
is unlikely the only major chromatin remodeling axis in CRC
liver metastasis, as PU.1 have other downstream targets while
the DPP4 enhancers have other upstream regulators. More
generally, since metastatic cancers of various types have not
been consistently associated with specific driver mutations,[7]
targeting chromatin remodeling pathways of metastatic cancers
may provide additional treatment options in the future.
Previous reports showed that inhibition of DPP4 induced
breast and prostate cancer metastasis via the CXCL12/
CXCR4/mTOR axis and epithelial-to-mesenchymal transi-
tion (EMT).[48,49] This highlights the importance of context,
which includes cancer type, stage, and microenvironment. For
example, Notch receptor can act both as oncogene or tumor
suppressor in different cancer types.[50] TGF-𝛽 functions as
tumor suppressor in early-stage CRC but promotes metastasis
and immune evasion in late stage and metastases.[51,52] Simi-
larly, DPP4 seems to play dual roles in different cancer types
and highlights the opposing forces between cancer cell intrinsic
mechanisms and the microenvironment.
Unlike the colon, the liver environment consists of hepato-
cytes, Kupffer cells, stellate cells, and sinusoidal endothelial cells
(LSECs).[53] Several major hepatic acellular factors, including
HGF, CXCL8, VEGF, MAPK, TGF-𝛽, NF-𝜅B, and CEA, have been
Figure 4. PU.1 upregulates DPP4 expression through remodeling DPP4-associated chromatin. A) Integrated analysis of JASPAR, RNA-seq, and ATAC-
seq revealing three potential DPP4 epigenetic regulators. B) Corresponding scores of the potential DPP4 regulators. C) Nucleosome occupancy analysis
of enriched or constitutive peaks from liver metastases or primary CRC centered at PU.1 motif with 300 bp flanking window. D) ChIP-qPCR showing
PU.1 binding in DPP4 promoter and enhancer regions. E,F) ChIP-qPCR showing PU.1 binding to DPP4 promoter and enhancers in HT29-derived liver
metastases versus primary tumors from E) CRC orthotopic-model, and F) patient-derived CRC organoids. G) Western blots showing DPP4 expression
levels in HT29 or CRC57 carrying scrambled (control) or PU.1 knockdown (PU.1 KD1 or KD2) shRNAs constructs. H) ChIP-qPCR showing relative
H3K27ac, H3K4me1, H3K4me3, and H3K9ac enrichments in HT29 or CRC57 carrying scrambled (control) or PU.1 knockdown (PU.1 KD1) shRNA
constructs. LM, liver metastases. CP, CRC primary tumor. E1, E2, and E3, enhancer 1, enhancer 2, and enhancer 3. Data represent the mean ± s.d.
p-values were calculated based on Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Figure 5. PU.1 is upregulated in CRC liver metastases and promotes CRC progression. A) Analysis of differential PU.1 expression in GEO dataset
(GSE41568) between primary CRC and liver metastases. B) Analysis of differential PU.1 expression in the RNA-seq dataset SRR2089755 from five
matched patient primary CRC and liver metastases. C) IHC staining of differential PU.1 expression between primary CRC and liver metastases. (Scale
bar, 100 um). D) Western blots showing DPP4 expression levels in paired primary CRC and liver metastases collected from four patients. E) Western
blots showing DPP4 expression levels in paired primary CRC and liver metastases-derived organoids collected from two patients (CA197 and CA1006).
Adv. Sci. 2021, 2004673 © 2021 The Authors. Advanced Science published by Wiley-VCH GmbH2004673 (10 of 15)
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shown to promote liver metastasis via the promotion of prolif-
eration, angiogenesis, EMT, and cell attachment.[54–60] In addi-
tion to these hepatic factors, hormones, and cytokines, such as
insulin, IGF-1, estrogen, and bile acid, make the liver a unique
environment.[61] The development of a metastatic niche follow-
ing the arrival of tumor cells is critical to liver metastases and
progression.[62] For instance, the IL-6–STAT3–SAA pathway in
hepatocytes establishes a pro-metastatic niche for the seeding
and growth of pancreatic cancer in the liver.[63] Therefore, HGF
is unlikely the sole factor; rather, it is probably among a group
of hepatic cytokines, chemokines, hormones, and growth factors
that drives reprogramming of CRC cells.
The “seed and soil” hypothesis proposed that interactions be-
tween metastatic cells and their organ microenvironment are im-
portant and may play a role in organ tropism.[8] As metastatic
loci have not been consistently associated with specific onco-
driver mutations,[4–7] our study suggests that epimutations may
provide an alternative mechanism for metastatic cells to adapt
to and evolve in the new niche. However, like genetic muta-
tions, most epimutations are likely “passengers” that do not have
any functional consequence. By combining footprinting analy-
sis, nucleosome occupancy analysis, and CRISPR/dCas9KRAB or
CIRSPR/dCas9HDAC editing, we managed to identify and vali-
date chromatin-remodeling transcription factors and regulatory
elements that functionally impact metastatic tumors. Identifi-
cation of these oncodriver epimutations may explain the lack
of metastasis-specific oncodriver mutations and hold the key to
understanding interactions between metastatic tumor cells and
their niche for new therapeutic development.
4. Experimental Section
Animal Procedures: All animal procedures were approved by
Duke University DLAR following the protocol A286-15-10. NOD.Cg-
Prkdcscidil2rgtm1Wjl/SzJ (NSG) mice and BALB/c mice used in this study
were 8 weeks old. To test DPP4 inhibition in vivo, three days after spleen
injection, Sitagliptin (Millipore Sigma, Cat#Y0001812) was administered
to mice twice a day via oral gavage at 250 mg kg−1.[64] To test HGF
inhibition in vivo, three days post spleen injection, Norleual (Tocris,
Cat#5369) was administered to mice i.p. twice a day at 1 mg kg−1.[65]
Cell Culture: Human CRC cell line HT29, patient derived xenograft
(PDX) human CRC cell lines CRC57, CRC247, and CRC12x, and BALB/c
mouse syngeneic colon cancer cell line CT26 were used in the study. These
cell lines were cultured in RPMI 1640 complete medium supplemented
with 10% FBS and 1% penicillin streptomycin solution. Engineered cell
lines expressing mCherry and luciferase were established according to the
published procedure.[12]
Western Blot Analysis: Western blot analysis was performed following
the previously described protocol.[66] Antibodies used in this study include
anti-human DPP4 antibody (1:1000, Abcam, ab28340), anti-human PU.1
antibody (1:1000, Abcam, ab88028), anti-phospho-(Ser/Thr) Phe antibody
(1:1000, Cell Signaling Technology, 9631S), and anti-actin (1:1000, Cell Sig-
naling Technology, 4970). Full scans of western blots are included in Fig-
ures S9,S10, Supporting Information.
Cecum Injection, Spleen Injection, Intrahepatic Injection and IVIS Imaging:
Cecum injection and spleen injection were performed following the previ-
ously published procedures.[67–69] Briefly, 1 × 106, 1 × 105, or 2.5 × 105
engineered cells carrying luciferase/mCherry were injected into the mouse
cecal wall, spleen, or liver, respectively. Spleen removal was performed fol-
lowing the described protocol.[33] The IVIS luciferase imaging system 200
(Xenogen) was used to detect the luciferin luminescent signal to examine
in vivo tumor development and liver metastases after sacrificing the mice.
ATAC-seq and RNA-seq: Four weeks post cecum injection, primary ce-
cum tumors and metastatic liver tumors were dissociated into single cells
using the human tumor dissociation kit (Miltenyi Biotec, Cat#130-095-
929). CRC cells were sorted by FACS (SONY SH800) based on mCherry
signal. ATAC-seq libraries were made from 50 000 CRC cells of each bi-
ological replicate following the previously described protocol,[21] and the
tagmented nuclei was sequenced using an Illumina PE, 2 × 150 bp. Total
RNA was isolated using Qiagen RNeasy Mini kit according to the man-
ufacturer’s instructions. RNA-seq libraries were made and sequenced by
Duke GCB by Illumina Hiseq 4000 SE 50 bp.
TaqMan qPCR: Total RNA was extracted from the cells using Qiagen
RNeasy Mini kit. cDNA was synthesized using the High-Capacity cDNA
Archive Kit (Thermofisher Scientific). Quantitative PCR was carried out us-
ing the TaqMan Gene Expression Assay (Thermofisher Scientific) to detect
DPP4 (Hs00897391).
Co-Immunoprecipitation: Immunoprecipitation assays were per-
formed using an immunoprecipitation kit (Abcam, ab206996) and
following the manufacturer’s instructions. Briefly, the cells were lysed
in RIPA buffer, and anti-human PU.1 antibody (1:100, Thermofisher
Scientific, PA5-17505) was added into the lysate before overnight incu-
bation at 4 °C. Protein G-conjugated beads were added to pull down the
specific protein complex interacting with PU.1. Western blot analysis was
performed on the eluted complex using anti-human C/EBP𝛼/𝛽 (1:1000,
Abcam, ab40764, and ab32358) and anti-human SMARCB1 (1:1000,
Thermofisher Scientific, PA5-40834).
Chromatin Immunoprecipitation and qPCR: Chromatin immunopre-
cipitation (ChIP) was performed using the ChromaFlash High-Sensitivity
ChIP Kit (EpiGentek, P-2027) according to the manufacturer’s instruc-
tions. Briefly, the cells were fixed by 1% formaldehyde for 10 min at room
temperature to crosslink the protein and DNA. Lysis buffer was added, and
the cells were centrifuged to collect the chromatin pellets, which were son-
icated to generate DNA fragments fewer than 500 base pairs in length and
then incubated with the specific antibody overnight at 4 °C. The antibod-
ies in this study included anti-PU.1 (1:100, Thermofisher Scientific, PA5-
17505), anti-H3K4me1 (1:100, Abcam, ab8895), anti-H3K4me3 (1:100,
Abcam, ab8580), anti-H3K9ac (1:100, EpiGentek, A-4022-050), and anti-
H3K27ac (1:100, Active motif, 39133). The enriched DPP4 DNA was pulled
down by antibody, and qPCR was performed to quantitate DPP4 enrich-
ment. The primers used for qPCR of DPP4-F and DPP4-R were AGACTG-
GCACAGTTTTCTGAG and CTTTCCCATCACCCTTGCTGT, respectively.
Flow Cytometry for Neutrophil Analysis: Cecum primary tumors and
metastatic liver tumors harvested from the cecum injection mouse model
were disassociated into single cells using the human tumor dissociation
kit (Miltenyi Biotec, Cat#130-095-929). Single cells were then incubated
with anti-CD11b-FITC (1:500, BD Bioscience, 557396) and anti-Ly6G-PE
(1:500, Thermofisher Scientific, 50-112-2445) antibodies. The stained cells
were analyzed by flow cytometry.
Neutrophil Cytotoxic Assay: The neutrophil cytotoxic assay was per-
formed following the protocol described previously.[39] Neutrophils were
isolated using the MojoSort Mouse Neutrophil Isolation Kit (BioLegend,
480057) from the mouse peripheral blood collected by cardiac punch. Five
thousand tumor cells carrying luciferase were seeded into the 96-well plate
F,G) Images and quantification of F) bioluminescence and G) survival analysis of NSG mice injected with luciferase-labeled HT29 carrying scrambled
(control) or PU.1 knockdown (PU.1 KD1 or KD2) shRNA constructs. H,J) Images and quantification of H) bioluminescence and J) survival analysis of
NSG mice injected with luciferase-labeled CRC57 carrying scrambled (control) or PU.1 knockdown (PU.1 KD1 or KD2) shRNA constructs. LM, liver
metastases. CP, CRC primary tumor. Data represent the mean ± s.e.m. in (A) and (B), and the mean ± s.d. in (F) and (H). p-values were calculated
based on Student’s t-test (A) and (B), log-rank test in (G) and (J), and ANOVA and Tukey’s HSD post hoc test in (F) and (H). *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
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four hours before coculture. Then, isolated neutrophils were co-cultured
with tumor cells (100:1) for 12 h. At endpoint, the live cells were mea-
sured by the Luminescent Cell Viability Assay (Promega, G7570). During
the coculture, live imaging was taken by the ImageXpress Pico System to
monitor the process of neutrophil migration.
Neutrophil Chemotaxis Assay: The neutrophil chemotaxis assay was
designed as previously described.[70] Briefly, 5 × 105 isolated neutrophils
suspended in OptiMEM (Invitrogen) supplemented with 0.5% FBS were
seeded into the upper chambers of CytoSelect 96-Well Transwells (3 μm
pore membrane) (Cell Biolabs, CBA-104/02963-726). Then, 400 ng human
CXCL6 (PeproTech, 300–41), mouse Cxcl6 (PeproTech, 250-17), cleaved
human CXCL6 and mouse Cxcl6 by active enzymatic DPP4 (BioLegend,
764102) were added into the lower chamber containing OptiMEM (Invitro-
gen) supplemented with 0.5% FBS. The transwells were incubated for 5 h
at 37 °C and 5% CO2. The migrated neutrophils were measured follow-
ing the manufacturer’s protocol (Cell Biolabs, CBA-104/02963-726). The
DPP4 activity assay was modified according to the manufacturer’s proto-
col (BioLegend, 764102) and previously described methods.[37] For this
study, 400 ng DPP4 was incubated with 400 ng hCXCL6 or mCxcl6 for
30 min at 37 °C in reaction buffer (25mm Tris-Cl, PH8.0). After the reaction,
DPP4 was removed by 30KWM ultra centrifugal filters (Sigma Millipore,
UFC5030).
Analysis of Tissue Microarrays: Tissue microarrays ZL-HLin-
Age075Met-01 (Zhuoli Biotechnology Co, China) were stained using
anti-DPP4 antibody (1:200, Abcam, ab215711) or anti-Myeloperoxidase
(1:100, Abcam, ab208670) and reviewed by a board-certified pathologist
specializing in tumor biology who had no prior knowledge of the patient
information for the tumor tissues. Each tissue core on the tissue microar-
ray was given a score of 0–3 based on intensity of staining. Scores of 0
are interpreted as negative for protein expression, and scores of 1, 2, and
3 are interpreted as positive staining for each tissue core.
Patient Specimens: The primary and liver metastatic CRC specimens
were obtained from the 7th Medical Center of PLA General Hospital
with informed consent by all donors. All studies were approved by the
Ethics Committee of the 7th Medical Center of PLA General Hospital
and the Institute of Biophysics, Chinese Academy of Sciences (2020-39).
Matched patient primary tumor and liver organoids were provided under
IRB 13–1159 (Cleveland Clinic Foundation). Organoids were screened for
mycoplasma contamination and syngeneic identity was confirmed using
Short Tandem Repeat (Duke University).
CRISPR/dCas9KRAB and CRISPR/dCas9HDAC Libarary Design and Screen-
ing: To test the potential epigenetic regulatory functions of the four
DPP4 regulatory elements (three enhancers and the promoter), we
used the CRISPOR algorithm to identify gRNA protospacers within each
regulatory region and identify possible off-targets on other regions of
the genome.[71] For each regulatory region, the gRNAs were selected
to minimize the off-target alignments. We selected 15, 18, 16, and 29
gRNAs to target enhancer 1, 2, 3, and the promoter of DPP4 to completely
span these regions. The gRNAs were put into pLV hU6-sgRNA hUbC-
dCas9-KRAB-T2a-Puro construct (Addgene, 71236), and were delivered to
HT29 cells via lentiviral infection as previously described.[30] We followed
the previously published method to construct the CRISPR/dCas9HDAC
libarary.[31] Briefly, the gRNAs targeting DPP4 promoter were cloned into
pLV U6-gRNA-UbC-eGFP-P2A-Bsr (Addgene 83925), which were delivered
to HT29 cells via lentiviral infection together with dCas9-hHDAC3 con-
struct (Addgene 98591). The sequences of the guide RNAs were shown
in Table S7, Supporting Information.
Quantification and Statistical Anlaysis—ATAC-seq and RNA-seq: ATAC-
seq data was processed using the pipeline developed for ENCODE to
perform quality control, filtering of low-quality reads and PCR duplicates,
analysis of reproducibility, reference genome alignment, peaks calling, and
fold-enrichment or p-value signal tracks generation. Reads were aligned to
reference genome hg19 using Bowtie2. Duplicate and mitochondrial reads
were removed, and peaks were called by MACS2.
RNA-seq raw sequencing reads were quality checked using Fastp[72]
and summarized with MultiQC.[73] Transcripts were aligned to reference
genome hg19 using Hisat2[74] and quantified by HTSeq.[75] EdgeR was
used for differential expression analyses.[76] Genes DE in liver metastases
were classified by p-value ≤ 0.05 and log2FC ≥ 0.8, whereas genes DE in
colon primary tumor were classified by p-value ≤ 0.05 and log2FC ≤ −0.8.
Differential Peak Calling and Annotation: Differential peaks were iden-
tified using DiffBind with a minimum of two biological replicates.[22] The
fold-changes of peaks were evaluated by the EDGER_BLOCK method in
the DiffBind package. Peaks with p-value ≤ 0.05 and |log2FC| ≥ 0.9 were
considered “differentially accessible”, where peaks with positive log2FC
were enriched in liver metastases and peaks with negative log2FC were en-
riched in CRC primary tumors. Peaks annotation was performed by using
the findMotifsGenome.pl command in the HOMER2[77] software based
on the nearest TSS. The R package ChIPseeker was also used to annotate
peaks and visualization.[23] Gene Ontology was performed by the R pack-
age clusterProfiler.[78]
Nucleosome Occupancy Analysis: For nucleosome occupancy analysis,
Broadpeak files per condition were merged and extended by 100 bp on
each side. Filtered Bam files were pooled and used as inputs for the Nu-
cleoATAC software to obtain occupancy scores.
Statistical Analysis: Data was expressed as mean ± standard deviation
(s.d.) of no smaller than three biological replicates. Student’s t-tests were
used for comparisons, while ANOVA followed by Tukey’s HSD post hoc
test (JMP 15) was used for multiple comparisons. All statistical tests were
conducted at the two-sided 0.05 p-value of significance. Patient data were
expressed as mean ± standard error of the mean (s.e.m.). Mice were ran-
domly allocated to experimental groups. Survival curves were estimated
using the Kaplan–Meier method and compared using the log-rank test.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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Figure 6. HGF upregulates DPP4 through activaton of PU.1. A) Dotplot of pathway analysis on enriched accessible chromatin regions in HT29 liver
metatases. B) Western blots showing PU.1 expression level in HT29 or CRC57 cells treated with or without HGF. C) Western blots showing PU.1
phosphorylation in HT29 or CRC57 cells treated with or without HGF or the c-Met inhibitor PHA665752. D,E) Western blots showing that PU.1 complexed
with D) C/EBP𝛼 and -𝛽 and E) SMARCB1. F) ChIP-qPCR showing relative H3K27ac, H3K4me1, H3K4me3, and H3K9ac enrichments in HT29 or CRC57
cultured in RPMI1640 media supplemented with or without 100 ng mL−1 HGF. G) Western blots showing the expressions of DPP4 in HT29 or CRC57
carrying scrambled (control) or PU.1 knockdown shRNA cultured in RPMI media supplemented with or without 100 ng mL−1 HGF. H,I) Images and
quantification of H) bioluminescence and I) survival analysis of NSG mice spleen-injected with luciferase-labeled HT29 cells receiving i.p. administered
PBS (control) or the HGF inhibitor Norleual. Data represent the mean ± s.d. in (F) and (H). p-values were calculated based on Student’s t-test (F) and
log-rank test in (I). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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